Novartis wins FDA nod for Rydapt, a new targeted drug for acute myeloid leukemia

Fierce Pharma -------- Novartis, which reported a good first quarter this week, has started the second quarter with good news today by winning FDA approval for Rydapt, its new breakthrough treatment for acute myeloid leukemia (AML), which is expected to generate more than $250 million in annual sales in the next few years. The FDA said it approved midostaurin for patients that have acute AML and the specific genetic mutation called FLT3. It was approved for use with a companion diagnostic. The kinase inhibitor, which works by blocking several enzymes that promote cell growth, is approved in combination with chemotherapy. It was also approved for adults with certain types of rare blood disorders. To learn more click on the picture below to read the article.